Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)

Posted on 24 February 2017

Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).

Read on

CANTAB Mobile awarded FDA clearance

Posted on 25 January 2017

Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration ('FDA') to market its CANTAB Mobile product as a medical device in the U.S.

Read on

Autifony Therapeutics Continues Evaluation of AUT00206 for the Treatment of Schizophrenia

Posted on 12 January 2017

Autifony Therapeutics recently presented a poster at the American College of Neuropsychopharmacology following their first human Phase I study in healthy male volunteers to investigate a novel treatment for the positive, negative and cognitive symptoms of schizophrenia. 

Read on

Cambridge Cognition Partners with The Cure Parkinson’s Trust

Posted on 11 January 2017

Cambridge Cognition has chosen The Cure Parkinson’s Trust (CPT) as beneficiary Charity of the Year for 2017.

Read on